文献速递肝肾功能剂量调整特殊人群用药

轻中度肝损伤对利司扑兰药代动力学的影响

Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam.
PubMed 文献 · Br J Clin Pharmacol · 2022-04-01

这项I期、多中心、开放标签、非随机、平行组、两部分研究评估了单次口服5 mg利司扑兰在轻度(Child-Pugh A级)或中度(Child-Pugh B级)肝损伤受试者中的药代动力学、安全性和耐受性。结果显示,与肝功能正常者相比,轻中度肝损伤对利司扑兰的药代动力学无临床相关影响,无需调整剂量。

要点

  • 轻中度肝损伤对利司扑兰暴露量的影响无统计学显著性。
  • 轻中度肝损伤受试者中未观察到新的利司扑兰相关安全性发现。
  • 轻中度肝损伤患者使用利司扑兰无需调整剂量。

核心结论

  • 轻或中度肝损伤对利司扑兰的药代动力学无临床相关影响,因此无需调整剂量。

研究设计与样本

  • I期、多中心、开放标签、非随机、平行组、两部分研究。
  • 成年受试者(18-70岁)按性别、年龄、体重指数和吸烟状态与肝功能正常者匹配。
  • 轻度肝损伤为Child-Pugh A级(第1部分),中度肝损伤为Child-Pugh B级(第2部分)。
  • 每名受试者单次口服5 mg利司扑兰,测定利司扑兰及其代谢物M1的血浆浓度并比较药代动力学参数。

主要发现

  • 轻度肝损伤受试者中利司扑兰的AUCinf和Cmax分别较肝功能正常者约低20%和5%。
  • 中度肝损伤受试者中利司扑兰的AUCinf和Cmax分别较肝功能正常者约高8%和20%。
  • 上述差异无统计学显著性,几何最小二乘均值比的所有90%置信区间均跨越1。
  • 轻中度肝损伤受试者中未观察到新的利司扑兰相关安全性发现。

临床怎么用

  • 轻或中度肝损伤患者接受利司扑兰治疗时无需调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: This phase I, multicentre, open-label, nonrandomised, parallel-group, two-part study aimed to evaluate the effect of mild to moderate hepatic impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of risdiplam. METHODS: Adult subjects (aged 18-70 years) with mild (Child-Pugh Class A; Part 1) or moderate (Child-Pugh Class B; Part 2) hepatic impairment were matched with subjects with normal hepatic function on sex, age, body mass index and smoking status. Each subject received a single oral dose of 5 mg of risdiplam. Plasma concentrations of risdiplam and its metabolite M1 were measured and PK parameters were compared. Adverse events, laboratory abnormalities, vital signs and electrocardiogram measurements were assessed. RESULTS: After a single dose (5 mg) of risdiplam, the risdiplam PK parameters area under the plasma concentration-time curve from time zero to infinity and maximum observed plasma concentration were approximately 20% and 5% lower, respectively, in subjects with mild hepatic impairment and approximately 8% and 20% higher, respectively, in subjects with moderate hepatic impairment compared with subjects with normal hepatic function. These differences were not statistically significant; all 90% confidence intervals for geometric least squares-means ratios spanned unity. No new risdiplam-related safety findings were observed in subjects with mild or moderate hepatic impairment. CONCLUSION: Mild or moderate hepatic impairment did not have a clinically relevant impact on the PK of risdiplam. Therefore, no dose adjustment is required in patients with mild or moderate hepatic impairment when receiving risdiplam.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Kletzl H, Ajmi H, Antys I, et al. Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam. Br J Clin Pharmacol. 2022. PMID: 35301746. doi:10.1111/bcp.15319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。